STOCK TITAN
  1. Home
  2. News
  3. TNXP

Tonix Pharmaceuticals Holding Corp - TNXP STOCK NEWS

Welcome to our dedicated news page for Tonix Pharmaceuticals Holding (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceuticals Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tonix Pharmaceuticals Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tonix Pharmaceuticals Holding's position in the market.

News
Tonix Pharmaceuticals Presents Data from its Horsepox-Based Vaccine Development Platform at the World Vaccine Congress Europe
Rhea-AI Summary
Tonix Pharmaceuticals presents preclinical data on its horsepox-based live virus vaccine platform at the World Vaccine Congress Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
News
Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models
Rhea-AI Summary
Tonix Pharmaceuticals announces enrollment in a Phase 1 clinical trial for TNX-1500 to prevent kidney allograft rejection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none
-
News
Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. to present at ThinkEquity Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. to present at World Vaccine Congress Europe
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
-
News
Tonix Pharmaceuticals Provides Overview of TNX-2900 Program for the Treatment of Prader-Willi Syndrome at the Foundation for Prader-Willi Research Family Conference
Rhea-AI Summary
Tonix Pharmaceuticals presents TNX-2900 program for Prader-Willi syndrome at FPWR conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
-
News
Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. has been granted a European patent for its magnesium-containing oxytocin formulations for treating pain, including migraine headaches. The patent is expected to provide market exclusivity in Europe until 2036. The company also holds U.S. patents that provide market exclusivity in the U.S. until 2036. Tonix completed enrollment in its Phase 2 study for the prevention of migraine headache and expects topline results in December 2023. The company believes that its strong patent position and unique approach have the potential to help chronic migraine sufferers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.55%
Tags
none
News
Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces public offering of common stock and warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.43%
Tags
offering
-
News
Tonix Pharmaceuticals Announces Proposed Public Offering
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. plans to offer and sell shares of its common stock and warrants in a public offering, with the proceeds going towards working capital, facilities, and product acquisition or licensing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.43%
Tags
offering
-
News
Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. has announced that the University of North Carolina Institute for Trauma Recovery has received a $3 million grant from the Department of Defense to investigate the potential of TNX-102 SL to reduce the frequency and severity of adverse effects of acute trauma. The proposed trial will examine the safety and efficacy of TNX-102 SL in reducing posttraumatic neuropsychiatric sequelae among trauma survivors. The trial will enroll approximately 180 participants and is anticipated to begin in early 2024. This funding and trial could lead to the development of a new treatment option for trauma and traumatic stress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags
none
News
Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023
Rhea-AI Summary
Tonix Pharmaceuticals presents positive data on mTNX-1700 in treating colorectal cancer at CICON23 conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
clinical trial
Stock TNXP logo
Tonix Pharmaceuticals Holding Corp

Nasdaq:TNXP

TNXP Rankings

#5235 Ranked by Market Cap
#5322 Ranked by Stock Gains
N/A Ranked by Dividends

TNXP Stock Data

15.53M
84.49M
0.01%
19.85%
1.7%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Chatham

About TNXP

tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.